Radical Catheter Gains FDA Clearance for 6F Device

LOS GATOS, Calif., April 13, 2026

Radical Catheter Technologies has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its 6F neurovascular access catheter, marking a significant advancement in the company’s mission to expand access and improve outcomes in neuroendovascular procedures. This latest approval strengthens the company’s best-in-class catheter platform and enhances its ability to address a wide range of clinical applications, particularly in middle meningeal artery (MMA) embolization and radial access procedures.

Expanding Neurovascular Access with Advanced Catheter Design

The newly cleared 6F catheter builds upon Radical’s previously approved devices, offering enhanced flexibility, stability, and performance in complex neurovascular interventions. Designed using patented ribbon technology, the catheter enables a unique combination of pushability, durability, and navigational precision, which are critical for physicians operating in challenging anatomical environments.

A key advantage of the 6F catheter lies in its thinner wall construction, allowing for a larger inner diameter relative to outer diameter, thereby facilitating the efficient delivery of therapeutic devices. Additionally, its smooth, continuous inner liner supports seamless device passage, reducing procedural friction and improving overall workflow efficiency. These innovations collectively position the catheter as a preferred choice for both radial and femoral access approaches, offering clinicians greater flexibility in treatment strategies.

The expanded platform is particularly impactful for procedures such as MMA embolization, a rapidly growing technique used in the treatment of chronic subdural hematomas. By enabling improved access and device compatibility, the 6F catheter enhances clinical precision and procedural success rates, ultimately contributing to better patient outcomes.

Driving Innovation in Neuroendovascular Procedures

The FDA 510(k) clearance underscores Radical Catheter Technologies’ commitment to addressing long-standing performance gaps in neurovascular devices. Physicians have historically faced challenges balancing catheter flexibility with structural stability, especially in complex cases involving tortuous vascular anatomy. The Radical platform directly addresses these challenges by delivering optimal mechanical performance without compromising durability.

Clinical experts have highlighted the significance of this advancement, noting that the lower profile and superior design of the 6F catheter make it particularly effective in demanding scenarios. Its ability to perform across multiple access routes further reinforces its role as a versatile and high-performance solution in modern neurointerventional practice.

Beyond individual device innovation, Radical is actively building a comprehensive neurovascular ecosystem, integrating its catheter technologies with complementary solutions from the NeuroTechnology Investors (NTI) portfolio. This includes advanced therapeutic devices such as next-generation stent systems, enabling a more holistic approach to neurovascular treatment.

Strengthening Commercial Strategy and Market Expansion

The approval of the 6F catheter also represents a critical milestone in Radical’s commercial expansion strategy, as the company continues to scale its specialized neurovascular commercialization team. By combining cutting-edge technology with targeted market deployment, Radical aims to accelerate adoption among leading healthcare institutions and interventional specialists.

The company is leveraging its collaboration with NeuroTechnology Investors to broaden its portfolio and enhance market reach, integrating innovative technologies that complement its catheter platform. This strategic alignment positions Radical to deliver end-to-end solutions for neurovascular care, addressing both access and therapeutic needs.

Looking ahead, Radical Catheter Technologies plans to showcase its patented platform and expanding product portfolio at major industry events, including the Society of Neurointerventional Surgery (SNIS) Annual Meeting, where it will engage with clinicians and stakeholders to demonstrate the clinical and operational advantages of its solutions.

As the demand for advanced neurovascular interventions continues to grow, the introduction of the 6F catheter reinforces Radical’s position as a leader in medical device innovation, offering technologies that enhance procedural efficiency, expand treatment capabilities, and improve patient care. With its latest FDA clearance, the company is well-positioned to drive the next wave of innovation in neuroendovascular therapy, delivering impactful solutions across a wide spectrum of clinical applications.

Source: Radical Catheter Technologies press release